CARsgen Therapeutics Holdings Limited (HKG:2171)
15.75
+0.19 (1.22%)
Jun 18, 2026, 4:08 PM HKT
HKG:2171 Revenue
In the year 2025, CARsgen Therapeutics Holdings had annual revenue of 125.66M CNY with 218.74% growth. CARsgen Therapeutics Holdings had revenue of 74.70M in the half year ending December 31, 2025.
Revenue
125.66M CNY
Revenue Growth
+218.74%
P/S Ratio
66.17
Revenue / Employee
353.98K CNY
Employees
355
Market Cap
9.25B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 125.66M | 86.24M | 218.74% |
| Dec 31, 2024 | 39.43M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 25.81M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Haohai Biological Technology | 2.73B |
| Everest Medicines | 1.90B |
| HBM Holdings | 1.23B |
| Lepu Biopharma | 1.04B |
| Ascentage Pharma Group International | 638.89M |
| CStone Pharmaceuticals | 299.99M |
| Nanjing Leads Biolabs | 197.25M |
| Suzhou Ribo Life Science | 165.26M |
CARsgen Therapeutics Holdings News
- 3 days ago - CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026 - PRNewsWire
- 17 days ago - Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting - PRNewsWire
- 3 months ago - CARsgen Therapeutics Announces 2025 Annual Results - PRNewsWire
- 4 months ago - CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai - PRNewsWire
- 5 months ago - CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors - PRNewsWire
- 5 months ago - Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors - Business Wire
- 6 months ago - CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596 - PRNewsWire
- 6 months ago - CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting - PRNewsWire